
ãã¡ã€ã¶ãŒå¹æ æ¿åºå ±åæžã«ãããšãCOVIDã¯ã¯ãã³ã«ããèªå·±å ç«äžå šçå矀ã¯ãéå»2幎éã«æ¬§ç±³ã§çºçãã200äžäººã®éå°æ»äº¡ã®åå ã®äžéšã§ããããšã瀺åãããŠããŸãã
å
èšäºã¯ãã¡ããã/Click here to read the original article.
ç±³åœãã«ããããªãŒã¹ãã©ãªã¢ããã¥ãŒãžãŒã©ã³ããè±åœããšãŒãããã®ã»ãšãã©ã®åœããåºãããæè¿ã®å ±åæžã«ãããšãã³ããã19泚å°ã®å€§éå°å
¥ä»¥æ¥ã200äžäººã®éå°æ»äº¡ãèšé²ãããŠããããšã確èªãããèŠéã鳎ããããŠããŸãã
ããªãæ¹ã®æ¿åºãšäž»èŠã¡ãã£ã¢ã¯ããã®è¡æçãªæ»è
ã®å¢å ã®åå ã¯åãªãå¶ç¶ã§ãããšäž»åŒµãããæ°åå€åããå»çã®å±æ©ãããã«ã¯ããã³ã°ã»ã³ãããããšåä»ããããå¿æ°çãªã©ã®èšãèš³ãæããããŠããŸãã
ãããããã®èšŒæ ã«ãã³ããã19ã®æ³šå°ããçºå£²ä»¥æ¥èŠããã§ããéå°æ»äº¡ã®ãã¹ãŠã®åå ã§ã¯ãªããããããªãããå§åçã«å€§ããªèŠå ã§ããããšã¯æããã§ããããã®çç±ã®ã²ãšã€ã¯ãã³ããã-19泚å°ãå
ç«ç³»ã«äžãã圱é¿ã倧ããããšã§ãã
ã³ããã19ã®ã¯ã¯ãã³æ¥çš®ã¯ãå
ç«ã·ã¹ãã ã®ç¶æ
ãæ¹åããã©ãããããããé广ã«ãªãã®ã§ããæ¿åºã®å
¬åŒå ±åã«ãããšãåŒãèµ·ãããããã¡ãŒãžã¯éåžžã«æ·±å»ã§ãã³ããã¯ã¯ãã³èªçºæ§èªå·±å
ç«äžå
šçå矀ãšããèšãããããªãã»ã©ã§ããã
äžè¡šã®æ°å€ã¯ãçµæžååéçºæ©æ§ïŒOECDïŒããã³EuroMOMOã«ååœæ¿åºæ©é¢ããæäŸããããã®ã§ããç±³åœã®ããŒã¿ã¯ãçŸç 管çã»ã³ã¿ãŒããæäŸããããã®ã§ããè±åœã®ããŒã¿ã¯ãOffice for National StatisticsããæäŸããããã®ã§ãããããŠããªãŒã¹ãã©ãªã¢ã®ããŒã¿ã¯ãªãŒã¹ãã©ãªã¢çµ±èšå±ããæäŸããããã®ã§ãã
ã€ãŸãããããã¯ç¬ç«ããæšå®å€ã§ã¯ãªãã®ã§ããæ¿åºå ¬èªã®å ¬åŒãªæ°åãªã®ã§ãããããŠãããã¡ã€ãã»ã¢ã€ãºã諞åœãšãšãŒãããã®ä»ã®26ã«åœã¯ãã³ããã19泚å°ãæåã«ç·æ¥äœ¿çšèš±å¯ïŒEUAïŒãåŸãŠä»¥æ¥ã2022幎ã®34é±ãã49é±ãŸã§ã®ããŸããŸãªæ¥ä»ãŸã§ã«199äžäººã®éå°æ»äº¡ã被ã£ãŠããããšã瀺ããŠããŸãã

ã¢ã¡ãªã«ã¯2021幎ã«674,954人ã®è¶ éæ»äº¡ãçºçãããã®åŸ2022幎ã®ç¬¬49é±ãŸã§ã«434,520人ã®è¶ éæ»äº¡ãçºçããŠããŸãã

ããã¯ãã¢ã¡ãªã«å šåã§2幎匱ã§110äžäººã®è¶ éæ»äº¡ãçºçãããšããé©ç°çãªæ°åã«çžåœããã
äžæ¹ãé£åœã®ã«ããã§ã¯ã2021幎ã«35,318人ã®è¶ éæ»äº¡ãçºçããããã«2022幎ã®ç¬¬34é±ãŸã§ã«25,333人ã®è¶ éæ»äº¡ãçºçããŠããŸãã2020幎ã®53é±ç®ãŸã§ã®è¶ éæ»äº¡è æ°ã31,042人ã§ããããšãšæ¯èŒãããšããã®å·®ã¯æŽç¶ã§ãã
ãããã2020幎ã2021幎ãšãã«ç¬¬34é±ãŸã§ã®æ°åãèŠããšãå®ã¯2022幎ãå§åçã«éå°æ»äº¡ãå€ãææªã®å¹Žã§ãã£ãããšãæããã«ãªãã

2020幎ã®ç¬¬34é±ãŸã§ã«ãã«ããã¯17,888人ã®è¶ éæ»äº¡ãèšé²ããŠããã2021幎ã®ç¬¬34é±ãŸã§ã«ãã«ããã¯18,498人ã®è¶ éæ»äº¡ãèšé²ããŠããããããã2022幎ã®ç¬¬34é±ãŸã§ã«ãã«ããã¯25,333人ã®éå°æ»äº¡ãèšé²ããã³ããã19泚å°ã®å±éåã®2020幎ã«èšé²ãããéå°æ»äº¡ã®42ïŒ å¢ãšãªããŸããã
ãã¥ãŒãžãŒã©ã³ãã§ããç¶æ³ã¯åæ§ã§ããã

2021幎ã«2,169人ã®è¶ éæ»äº¡è ãåºããããã«2022幎ã®ç¬¬49é±ãŸã§ã«5,286人ã®è¶ éæ»äº¡è ãåºããšããè¡æçãªäºæ ã«èŠèããããããã¯ãæšå®äººå£500äžäººã®å°ããªå³¶ã«ãšã£ãŠãè¡æçãªæ°åã§ãã
ç¹ã«ãã³ãããã³ãããã¯ã®æçæãã³ããæ³šå°ã®å±éåã«äºæ³ãããããããè¶ éæ»äº¡ãçºçãããå®éã«160人å°ãªãæ»äº¡ãèšé²ããã2020å¹Žãšæ¯èŒãããšã
ã€ãŸãããã¥ãŒãžãŒã©ã³ãã¯ã2020幎ãŸã§ã®53é±ãšæ¯èŒããŠã2022幎ãŸã§ã®49é±ã§3,404%ãšããè¡æçãªè¶ éæ»äº¡ã被ã£ãããšã«ãªããŸãã
äžæ¹ãæãè¿ãé£åœã§ãããªãŒã¹ãã©ãªã¢ã§ã¯ã2021幎ã«11,068人ã®è¶ éæ»äº¡ãçºçãã2022幎ã®ç¬¬38é±ãŸã§ã«22,730人ã®è¶ éæ»äº¡ãšããè¡æçãªæ°åãåºãŸãããããã¯ãã³ãããã³ãããã¯ã®æçæã§ã³ããæ³šå°ã®å±éåã«1,306人ã®è¶ éæ»äº¡è ããèšé²ãããªãã£ã2020幎ãšã¯å šãå¯Ÿç §çãªãã®ã§ãã

ã€ãŸãããªãŒã¹ãã©ãªã¢ã¯ã2020幎ã®53é±ãšæ¯èŒããŠã2022幎ã®ããã39é±ã§1,640ïŒ ãã®è¶ éæ»äº¡ã被ã£ããšããè¡æçãªçµæãšãªã£ãŠããŸãã
æåŸã«ãè±åœæ¿åºããã³æ¬§å·ã®26ã®é¡æ¿åºããEuroMOMOã«æäŸãããå ¬åŒæ°å€ã«ãããšã倧éžã®å€§éšåã¯ã2021幎ã«375,253人ã2022幎ã«404,6000人ã®è¶ éæ»äº¡ã被ã£ãããšã倿ããã
è±åœæ¿åºã𿬧å·å šåã®26ã®é¡æ¿åºãEuroMOMOã«æäŸããå ¬åŒæ°å€ã¯ã倧éžã®ã»ãšãã©ã2021幎ã«375,253人ã®éå°æ»äº¡ã被ãã2022幎ã«ã¯404,6000人ã®éå°æ»äº¡ã被ãããšãæããã«ããŠããã

ããã¯ã2幎éã§779,853人ã®è¶ éæ»äº¡ã«çžåœããããã®æ°åã«ã¯ãŠã¯ã©ã€ãã¯å«ãŸããŠããªãã®ã§ãçŸåšé²è¡äžã®æŠäºã®ããã«ããããšã¯ã§ããªãã
ãã®æ°åãèŠãŠãç§ãã¡ã¯äžã€ã®çåãæ±ããããªããããã»ã©å€ãã®äººãæ»ãã§ããã®ãããšããããšã ããã®çãã¯ãäœå¶åŽãç§ãã¡ã®æåã®å©çã®ããã«åããªãããšãåãå ¥ããããšãã人ã ã«ã¯æããã§ãããäž»ãªçç±ã¯ãCovid-19ã®ã¯ã¯ãã³æ¥çš®ãã®ãã®ã§ããã
ããããããã¯ä»ã®çåã«ã€ãªããããã³ããã19ã®ã¯ã¯ãã³æ¥çš®ãã©ãããŠäººã殺ãããšãã§ããã®ãã
ãŸããå ¬åŒã®èšŒæ ã«ããã°ãå°ãªããšãçç±ã®1ã€ã¯ãã³ããã»ã¯ã¯ãã³ãå ç«ç³»ã«ç倧ãªãã¡ãŒãžãäžããããšã§ãããåŒãèµ·ãããããã¡ãŒãžã¯éåžžã«æ·±å»ã§ãã³ãããã¯ã¯ãã³èªçºæ§èªå·±å ç«äžå šçå矀ãšããèšãããããªãã
ãšã€ãºã¯HIVãŠã€ã«ã¹ã«ãã£ãŠã®ã¿åŒãèµ·ããããããããã¯äž¡è ã¯åããã®ã§ãããšããã®ã¯äžè¬çãªèª€è§£ã§ãã
å®ã¯ãAIDSïŒåŸå€©æ§å ç«äžå šçå矀ïŒã¯ãå ç«ç³»ãèããæå·ãããšãã«èµ·ãããçåœãè ããå¯èœæ§ã®ããå€ãã®ææçãç æ°ã衚ãååã«ãããŸããã
åŸå€©æ§å ç«äžå šçå矀ã®äººã¯ãéåžžãå ç«åã匱ã人ã«ããçºçããªãããããã¯å¥åº·ã§å ç«åããã人ãªã軜çã§æžããããªãç¹å®ã®ãããæ·±å»ãªææçã«ããããªã¹ã¯ãé«ããªããŸãã
ããã§ã¯ãã³ããã19ã¯ã¯ãã³ã被æ¥çš®è ã«åŸå€©æ§å ç«äžå šçå矀ïŒAIDSïŒããããã¯ã³ããã19ã¯ã¯ãã³èªçºåŸå€©æ§å ç«äžå šçå矀ïŒVAIDSïŒãšããèšãããã®ãªããåæ§ã®å±æ§ãæã€æ°èŠã®çŸæ£ãçºçãããŠãããšããäžé£ã®åŒ·ã蚌æ ã玹ä»ããŸãã

åèè³æA
ã¯ã¯ãã³ã®å¹æã¯è¡°ããªãããå ç«ã·ã¹ãã ã®æ§èœã¯è¡°ãã
ã¯ã¯ãã³ã®å¹æãšã¯ãã¯ã¯ãã³ã®å¹æã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœããã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãšæ¯èŒãããã®ã§ããã
äœãåããŠçްèã«ééãããšããææãä¹ãè¶ããããã«å¿ èŠãªãã¹ãŠã®çްèãšã®éãã®éå ·ãäœãã䜿çšããã®ã«æ°æ¥ãããããšããããŸããææåŸãå ç«ç³»ã¯ãã®ç æ°ããäœãå®ãæ¹æ³ã«ã€ããŠåŠãã ããšãèšæ¶ããã
ã¯ã¯ãã³ã¯ãææãæš¡å£ããããšã§å ç«ã®çºéãå©ãããšèšãããŠããŸããã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ããããæš¡å£ææããªããªããšãäœã«ã¯ãã¡ã¢ãªãŒãT现èãæäœãæ®ããå°æ¥ãã®ç æ°ãšã©ãéãããèšæ¶ããããã«ãªããŸãã
ã€ãŸããåœå±ããã¯ã¯ãã³ã®å¹æã¯æéãšãšãã«åŒ±ãŸãããšè¿°ã¹ãŠããã®ã¯ãæ¬åœã¯ãå ç«ã·ã¹ãã ã®æ§èœãæéãšãšãã«åŒ±ãŸãããšããæå³ãªã®ã§ãã

ã³ããã19ã®æ³šå°ã«é¢ããŠ-ã
ã¯ã¯ãã³å¹æãïŒ50ïŒ ã§ããã°ãå®å šæ¥çš®è ã¯æªæ¥çš®è ã«æ¯ã¹ãŠCovid-19ã«å¯ŸããŠ50ïŒ ä»¥äžé²åŸ¡ãããŠããããšã«ãªããŸããèšãæããã°ãå®å šãªã¯ã¯ãã³æ¥çš®è ã¯ãCovid-19ã«åãçµãã®ã«50ïŒ åªããå ç«ç³»ãæã€ãšããããšã§ãã
ã¯ã¯ãã³å¹æã0ïŒ ã§ããã°ãå®å šæ¥çš®è ã¯ã¯ã¯ãã³æªæ¥çš®è ãããCovid-19ã«å¯Ÿããé²åŸ¡åããªãããšãæå³ããã¯ã¯ãã³ã¯ç¡å¹ã§ããããšãæå³ãããèšãæããã°ãå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã¯ãã¯ã¯ãã³æªæ¥çš®ã®äººãšåçã®å ç«ã·ã¹ãã ã§ã³ãŽã£ã19ã«å¯ŸåŠã§ããããšã«ãªãã
ããããã¯ã¯ãã³ã®æå¹æ§ã-50ïŒ ã§ããã°ãã¯ã¯ãã³æªæ¥çš®è ã¯å®å šæ¥çš®è ãããã³ãã19ã«å¯ŸããŠ50ïŒ ä»¥äžé²åŸ¡ãããŠããããšã«ãªããèšãæããã°ãã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœã¯ãã¯ã¯ãã³æªæ¥çš®è ã®èªç¶å ç«ã·ã¹ãã ã®æ§èœããã50ïŒ æªããšããããšã«ãªãããããã£ãŠãCovid-19ã¯ã¯ãã³ã¯å ç«ç³»ã«ãã¡ãŒãžãäžããããšã«ãªãã
åèè³æB
è±åœã®ããŒã¿ã§ã¯ãã³ããã19ã¯ã¯ãã³ã¯çŸå®çã«ãã¬ãã£ããªå¹æãæã£ãŠãã
è±åœå¥åº·å®å šä¿éå±ïŒUKHSAïŒã¯ãã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒããæ¯é±çºè¡ããŠãããåã¬ããŒãã«ã¯ãã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19çäŸãå ¥é¢ãæ»äº¡ã«é¢ãã4é±éåã®ããŒã¿ãå«ãŸããŠããŸãã
以äžã¯ãUKHSA Vaccine Surveillance Report - Week 5 - 2022 - ããåŒçšãããã€ã³ã°ã©ã³ãã®18æ³ä»¥äžã®å幎霢局ã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººãããã®Covid-19çäŸçãšãã€ã³ã°ã©ã³ãã®å šæäººã®10äžäººãããã®å¹³åçäŸçã§ããã

10äžäººãããã®çäŸæ°ã¯ããã¹ãŠã®å¹Žéœ¢å±€ã§ã¯ã¯ãã³æªæ¥çš®è ã®äžã§æãå°ãªãã3åæ¥çš®è ã®çäŸæ°ã¯ã»ãšãã©ã®å¹Žéœ¢å±€ã§æªæ¥çš®è ã®çŽ2åã2åæ¥çš®è ã®çäŸæ°ã¯ã»ãšãã©ã®å¹Žéœ¢å±€ã§æªæ¥çš®è ã®çŽ3åã§ããããšãããããããã ããã§ãããã
ãã®ããŒã¿ã ãã§ãæãç±å¿ãªã¯ã¯ãã³æè·è ã§ãããæ·±ãæžå¿µããå¿ èŠããããŸãã
ããŠãçäŸçãããã£ããšããã§ããã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æèšç®åŒãçšããŠãå®éã®ã¯ã¯ãã³å¹æãèšç®ããŠã¿ãŸãããã
ã¯ã¯ãã³æªæ¥çš®è
ç - ã¯ã¯ãã³æ¥çš®è
ç / ã¯ã¯ãã³æªæ¥çš®è
ç = ã¯ã¯ãã³æå¹æ§
äŸïŒ18ïœ80æ³ä»¥äžã®äºç𮿷·åã¯ã¯ãã³ïŒ1,846.38 - 5,226.1 / 1,846.38 = ãã€ãã¹183ïŒ
ã
ãããã£ãŠã2022幎1æã®ã€ã³ã°ã©ã³ãã«ãããæäººå šäœã«å¯ŸããCovid-19ã¯ã¯ãã³å¹æã®å®æž¬å€ã¯ãå¹³åã§MINUS-183%ã§ããããšãããããŸããã
åäºéæ¥çš®å¹Žéœ¢å±€ã§Covid-19ã¯ã¯ãã³ã®æå¹æ§ã蚌æãããã®ã¯ä»¥äžã®éãã§ãã

Covid-19ã®ã¯ã¯ãã³å¹æãæãäœãã£ãã®ã¯ã2022幎1æãéããŠã€ã³ã°ã©ã³ãã®40-49æ³ã®ã°ã«ãŒãã§ããã€ãã¹209.4%ãèšé²ãã50-59æ³ã®ã°ã«ãŒããããã«å£ããªãçµæã§ããã
ããããå¿ããŠã¯ãªããªãã®ã¯ãåèè³æAã«ç€ºãã蚌æ ã§èšŒæããããã«ãã¯ã¯ãã³å¹æã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãšãã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒããææšã§ããããšã§ãã
ãããã£ãŠãUKHSAã®ããŒã¿ã¯ãã³ããã19泚å°ãèªç¶å ç«ç³»ã壿» ãããŠããããšãå®éã«ç€ºããŠããŸãã
åèè³æC
è±åœã®ããŒã¿ã§ã¯ãå®å šã«ã¯ã¯ãã³ãæ¥çš®ãã人ã¯ãå ç«ç³»ã®ããã©ãŒãã³ã¹ãäœäžããŠããããšãæããã«ãªã£ãŠããŸãã
å ç«ç³»ã®ããã©ãŒãã³ã¹ãç®åºããããã«ã¯ãã¯ã¯ãã³ã®æå¹æ§ãç®åºããéã«äœ¿çšããèšç®æ¹æ³ãå°ã倿Žããåèè³æBã«èšèŒãããŠããçäŸçã«åºã¥ããã¯ã¯ãã³æ¥çš®è ãŸãã¯æªæ¥çš®è ã®æå€§çäŸçã§çããå²ãå¿ èŠããããŸãã
æªæ¥çš®çäŸæ° - ã¯ã¯ãã³æ¥çš®çäŸæ° /æªæ¥çš®çäŸæ°ã®æå€§å€ / ã¯ã¯ãã³æ¥çš®çäŸæ° = å ç«ç³»ããã©ãŒãã³ã¹ äŸïŒ18-80æ³ä»¥äžã®äºç𮿷·åã¯ã¯ãã³ïŒ 1,846.38 - 5,226.1 / 5,226.1 = ãã€ãã¹-65%ã
次ã®ã°ã©ãã¯ã2022幎1æã«äºéã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ãåãããã¡ãŒãžã®çã®å€§ããã幎霢局å¥ã«ç€ºãããã®ã§ã-ã

ã€ãŸããã€ã³ã°ã©ã³ãã®å¹³åçãªäºéã¯ã¯ãã³æ¥çš®è ã¯ããŠã€ã«ã¹ã现èããããšæŠãããã®å ç«ã·ã¹ãã ãæåŸã®35%ãŸã§äœäžããŠããããšã«ãªããŸãããããããã®ããŒã¿ã¯åãªãäžéæ§ã®ãã®ãªã®ã§ããããããããšããå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã ã®å ç«ã·ã¹ãã ã®æ§èœã¯ãé±ããšã«äœäžããŠããã®ã§ããããã
åèè³æD
å®å šæ¥çš®éå£ã®å ç«ã·ã¹ãã ã®æ§èœãé±ããšã«äœäžããŠããããšã蚌æããè±åœã®ããŒã¿
UKHSAã®éå»ã®ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã«èšèŒãããŠããçäŸçãçšããã°ãé廿°ã¶æéã®çŸå®ã®ã¯ã¯ãã³å¹æã被æ¥çš®è ã®å ç«ç³»ã®ããã©ãŒãã³ã¹ã远跡ããããšãã§ããŸãã
ããã§ã以äžã®å ±åæžã«èšèŒãããŠããçäŸæ°ãçšããŠã¿ãŸããã
Covid-19 Vaccine Surveillance Report â Week 37â² (Published by PHE)
âCovid-19 Vaccine Surveillance Report â Week 41â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 45â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 49â (Published by UKHSA)
âCovid-19 Vaccine Surveillance Report â Week 1 â 2022â (Published by UKHSA)
ãããŠã2021幎8æ16æ¥ãã2022幎1æ2æ¥ãŸã§ã®éã«ãçŸå®ã®Covid-19ã¯ã¯ãã³ã®æå¹æ§ãç®åºããŸããã

æåã®ããŒã¹ã¿ãŒã·ã§ããã¯2021幎ã®37é±ç®ã«å®æœãããŸãããããã®ã°ã©ãã¯ããã®åŸã®2ã¶æéã§ã¯ã¯ãã³å¹æã®ããŒã¹ããæäŸããããšãæç¢ºã«ç€ºããŠããŸããããããæ®å¿µãªããããã®ããŒã¹ããããã«çæéã§ãã£ããã瀺ããŠããã49é±ç®ãã52é±ç®ã«ãããŠã³ããã19ã¯ã¯ãã³ã®æå¹æ§ã¯æãããã¬ãã«ãŸã§äœäžããŠããŸãã
次ã®ã°ã©ãã¯ã21幎8æ16æ¥ãã22幎1æ2æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããå šå¹Žéœ¢å±€ã®ç·åçãªå ç«ã·ã¹ãã ã®æ§èœã瀺ããŠããŸãã

äžèšãããããããã«ã40-49æ³ã¯22幎1æ2æ¥æç¹ã§æãå ç«åãäœäžããŠããããã€ãã¹60ïŒ ãèšé²ããŠãããå³è¡šCã§ã¯ã40-49æ³ã®å ç«ã·ã¹ãã ã®æ§èœã¯ã22幎1æ30æ¥ã«ã¯ãã€ãã¹67.7%ã«äœäžããŠããããšãããããŸãããã®ããšãããã³ããã19ã¯ã¯ãã³ã¯ãèªç¶å ç«ç³»ã«ãã¡ãŒãžãäžããé±ã远ãããšã«æªåããŠããããšããããã
åèè³æE
è±åœã®ããŒã¿ã§ã¯ãå®å šãªã¯ã¯ãã³æ¥çš®è ãCovid-19ã§æ»äº¡ãã確çãé«ããªããŸããã
以äžã®ã°ã©ãã¯ã第5é±ã®UKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒãã§èŠã€ãã£ãæ»äº¡æ°ãšããã«ã¯ã¯ãã³æ¥çš®è ã®èŠæš¡ããç®åºãããã€ã³ã°ã©ã³ãã®18æ³ä»¥äžã®å幎霢局ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19æ»äº¡çã§ãã

ããã«ã¯ã¯ãã³æ¥çš®è ã¯ã18-29æ³ãš40-49æ³ãé€ããã¹ãŠã®å¹Žéœ¢å±€ã§ã100kãããã®æ»äº¡çãæãé«ããããããä»åŸæ°é±éã§ããã®æ»äº¡çã2ã€ã®ç°åžžå€ã®éã§å ¥ãæ¿ããããšãäºæ³ãããŸããããã¯ãå³è¡šDã«åºã¥ããšãé±ããšã«ã¯ã¯ãã³æ¥çš®è ã®ç¶æ³ãæªåããŠããããšã蚌æãããŸãã
åèè³æF
è±åœã®ããŒã¿ã§ã¯ãã³ããã19ã¯ã¯ãã³ã¯æ»ã«å¯ŸããŠçŸå®çã«åŠå®çãªå¹æãçºæ®ããŠãã
æ»äº¡çãããã£ãã®ã§ãåã³ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æèšç®åŒãçšããŠãæ»äº¡ã«å¯ŸããçŸå®ã®ã¯ã¯ãã³å¹æãç®åºããããšãã§ããŸãã

22幎1æ3æ¥ãã1æ30æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããå®éã®æ»äº¡ã«å¯Ÿããã³ããã19ã¯ã¯ãã³ã®æå¹æ§ã¯ã80æ³ä»¥äžã§-110.24%ã70-79æ³ã§-97%ã18æ³ä»¥äžã®å šæäººã§å¹³å-98.14%ãšäœããã®ã§ããã
ããããå¿ããŠã¯ãªããªãã®ã¯ãåèè³æAã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãšãã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒããææšã§ããã
åèè³æG
è±åœã®ããŒã¿ã§ã¯ãé«éœ¢è ã®äžéšã¯ãã§ã«VAIDSãçºçããŠããå¯èœæ§ããããšãããŠãã
以äžã®ã°ã©ãã¯ãUKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒã第5é±ïŒ2022幎ïŒã®10äžäººãããã®Covid-19æ»äº¡çã«åºã¥ããå®å šæ¥çš®è ã®æ»äº¡ã«å¯Ÿããå ç«ã·ã¹ãã ã®æ§èœã瀺ããŠããŸãã

ã³ããã19ã®ã¯ã¯ãã³ã«ãã£ãŠå ç«ç³»ã«ãã¡ãŒãžãçãããããé±ã远ãããšã«æªåãããšããéå»ã®åŸåãããå ç«ç³»ã®ããã©ãŒãã³ã¹ãæãäœãã®ã¯ãæåã«ã¯ã¯ãã³ãæ¥çš®ãã人ãã¡ã§ããã80æ³ä»¥äžã-52.4%ããããŠ70ïœ79æ³ã-49.2%ã§ããããšãããããŸããã
ãããããã®ããŒã¿ã«ã¯æ°ã«ãªãç°åžžããããŸãã30ïœ39æ³ã®å¹Žéœ¢å±€ã§ã¯ãå ç«ç³»ã®ããã©ãŒãã³ã¹ã29ïŒ çšåºŠãã©ã¹ã«ãªãã¯ãã§ããã代ããã«-15.4ïŒ ãšãªã£ãŠããŸããããã«ã¯ããã€ãã®çç±ãèããããŸãããã©ããè¯ããšã¯èšããŸããã
30ïœ39æ³ã®å¹Žéœ¢å±€ãæ¬åœã«æªããªã£ãŠããã®ãããããã¯ä»ã®å¹Žéœ¢å±€ãç§ãã¡ãèšãããŠããããããã£ãšæªããªã£ãŠããã®ããã©ã¡ããã§ãã
ãããã«ãããã³ããã19ã®æ³šå°ã«ãã£ãŠãé«éœ¢è ã匱è ãå ç«ç³»ã倱ããã¯ã¯ãã³æ¥çš®è ãããã³ããã19ã§æ»äº¡ãã確çãé«ããªã£ããšããããšããããŒã¿ã確å®ã«äŒããŠããããšã¯ç¢ºãã§ãã
åèè³æH
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã®ããŒã¿ã§ã¯ãå®å šãªã¯ã¯ãã³æ¥çš®è ãCovid-19ã§æ»äº¡ãã確çãé«ããªã£ãã
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã¯ãã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19ã®çäŸãå ¥é¢ãæ»äº¡ã«é¢ããããŒã¿ãå«ãCovid-19çµ±èšã¬ããŒããæ¯é±çºè¡šããŠããŸãã
以äžã®ã°ã©ãã¯ã2æ2æ¥ïŒæ°ŽïŒã«çºè¡šãããå ±åæžã«ãããšã21幎12æ25æ¥ãã22幎1æ21æ¥ã®éã«ã¹ã³ããã©ã³ãã§èµ·ããCovid-19ã«ããæ»äº¡ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®å²åã瀺ããŠããŸãã

次ã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®å¹Žéœ¢æšæºåCovid-19æ»äº¡çã瀺ããŠããŸãããã®ããŒã¿ã¯ã22幎2æ2æ¥ïŒæ°ŽïŒã«çºè¡šãããPHS Covid-19çµ±èšå ±åæžã®54ããŒãžã«ãã衚16ããæœåºããããã®ã§ããã

1æ21æ¥ã«çµããçŽè¿ã®é±ã§ã¯ãå®å šæ¥çš®è ãã¯ã¯ãã³æªæ¥çš®è ã«æ¯ã¹ãŠCovid-19ã§æ»äº¡ãã確çã¯çµ±èšçã«2å以äžã§ããããšã倿ããã
ã¯ã¯ãã³æ¥çš®è ã®åæã®æé«æ»äº¡çã¯ã1æ15æ¥ã«å§ãŸãé±ã®10äžäººããã15.49人ã§ãã£ãããã¯ã¯ãã³æªæ¥çš®è ã®æé«æ»äº¡çã¯ã1æ8æ¥ã«å§ãŸãé±ã®10äžäººããã10.93人ã§ããã
åèè³æI
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã®ããŒã¿ã§ã¯ãCovid-19ã¯ã¯ãã³ã¯æ»ã«å¯ŸããŠçŸå®çã«åŠå®çãªå¹æãæã€ããšã瀺ãããŠãã
以äžã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãå ¬è¡è¡çå±ããæäŸãããæ°åã«ãããšã4é±éã«ãããæ»äº¡ã«å¯Ÿããå®éã®ã¯ã¯ãã³å¹æã瀺ããŠããŸãã

æ»äº¡ã«å¯Ÿããã¯ã¯ãã³å¹æã¯ãå°ãªããšã2021幎12æ25æ¥ãããã€ãã¹ã«ãªã£ãŠããã22幎1æ21æ¥ã®æç¹ã§ã¯ãã€ãã¹112ïŒ ãšããé©ç°çãªæ°åã«èœã¡èŸŒãã§ããŸãã
ããããããäžåºŠå¿ããŠã¯ãªããªãã®ã¯ãåèè³æAã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœãšã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãæ¯èŒããææšã§ããããšã§ãã
åèè³æJ
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã®ããŒã¿ã«ãããšãå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã®äžã«ã¯ããã§ã«VAIDSãçºçããŠãã人ãããå¯èœæ§ããããŸãã
以äžã®ã°ã©ãã¯ãã¹ã³ããã©ã³ãå ¬è¡è¡çå±ãæäŸããæ°åã«ãããšã1æ15æ¥ãã22幎1æ21æ¥ãŸã§ã®éã«ãæ»äº¡ã«å¯Ÿãããã¹ãŠã®å®å šæ¥çš®æäººã®å¹³åå ç«ã·ã¹ãã æ§èœã瀺ããŠããŸãã

å šæäººã®æ»äº¡ã«å¯Ÿããå ç«ç³»ã®å¹³åæçžŸã¯ãã¹ã³ããã©ã³ãã§ã¯-53ïŒ ã§ãåèè³æGã«ç€ºãã€ã³ã°ã©ã³ãã®å¹³å-50ïŒ ããããã«äžåã£ãŠããŸãã
ã€ãŸããã³ããã19ã®æ³šå°ã¯å¹æããªãã ãã§ãªããå ç«ç³»ã«ãã¡ãŒãžãäžããæ¥çš®è ãåŸå€©æ§å ç«äžå šçå矀ãçºçããã¯ã¯ãã³æªæ¥çš®è ãããæ»äº¡ãã確çãé«ããšããããšããããŒã¿ã確å®ã«äŒããŠããããšã«ãªããŸãã
åèè³æK
ã«ããæ¿åºã®ããŒã¿ã«ãããã³ããã19ã¯ã¯ãã³ãå ç«ç³»ãç Žå£ããŠããããšã確èªãããã
ã«ããæ¿åºCovid-19 Daily Epidemiological Updatesã®1æ15æ¥ã®æ°åãã12æ4æ¥ã®æ°åãåçŽã«åŒããšã21幎12æ5æ¥ãã22幎1æ15æ¥ãŸã§ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®æ£è æ°ã以äžã®ã°ã©ããšãªãã

ã«ããã§ã¯ã4th Decã®ã¬ããŒãã«ãããšã2,220äžäººãå°ãªããšã2åæ¥çš®ã2,320äžäººãå°ãªããšãäžéšæ¥çš®ããŠããŸããå ¬åŒçµ±èšã«ãããšã2020幎ã®ã«ããã®äººå£ã¯3,801äžäººãšæšå®ãããŠããŸãã
ãããã£ãŠãã«ããã§ã¯2310äžäººãCovid-19ã¯ã¯ãã³ãå°ãªããšã1åæ¥çš®ããŠãããããã«ããã§Covid-19ã¯ã¯ãã³ãæ¥çš®ããŠããªã人ã¯çŽ1481äžäººãšãªãã
以äžã®ã°ã©ãã¯ãäžèšã®äººå£èŠæš¡ãšçäŸæ°ã«åºã¥ããŠãã«ããã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººãããã®Covid-19çäŸçã瀺ããŠããŸãã

以äžã®ã°ã©ãã¯ãäžèšã®çäŸæ°ã«åºã¥ããŠã21幎12æ5æ¥ãã22幎1æ15æ¥ã®éã«ã«ããã§å®éã«è¡ãããCovid-19ã¯ã¯ãã³ã®æå¹æ§ã瀺ãããã®ã§ãã

ããããå¿ããŠã¯ãªããªãã®ã¯ãåèè³æAã§èšŒæããããã«ãã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœããã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãšæ¯èŒããææšã§ããããšã§ãã
次ã®ã°ã©ãã¯ã21幎12æ5æ¥ãã22幎1æ15æ¥ã®éã«ã«ããã§å®å šæ¥çš®ãåãã人ã ã®å ç«ç³»ã®ããã©ãŒãã³ã¹ã瀺ããŠããŸãã

ã¯ã¯ãã³æ¥çš®ãåããã«ãã人ã®å¹³åçãªå ç«åã¯ãããçš®ã®ãŠã€ã«ã¹ãããçš®ã®ãããªã©ãšéãããã®å ç«åã®18.45%ãŸã§äœäžããŠããŸããããããã¯ã¯ãã³æ¥çš®ãã«ããåœæ°ã«ããããããã®ã§ãã
åèè³æL
å®å šãªã¯ã¯ãã³æ¥çš®è ã¯Næäœãäœãããšãã§ããªã
è±åœå¥åº·å®å šä¿éå±ã¯ãã¯ã¯ãã³ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã ãã§ãªãããŠã€ã«ã¹ã®ä»ã®éšåã«å¯Ÿããæäœãç£çããææåŸã®äœã®çåŸçãªèœåã劚害ããããšãçºèŠããŸãããå ·äœçã«ã¯ãã¯ã¯ãã³æ¥çš®è ã¯ãã¯ã¯ãã³æªæ¥çš®è ã®åå¿ã«éèŠãªåœ¹å²ãæãããŠã€ã«ã¹ã®æ®»ã§ãããã¯ã¬ãªã«ãã·ãã¿ã³ãã¯è³ªã«å¯Ÿããæäœãç£çããªãããã§ãã

åèè³æM
ã³ããã-19ã¯ã¯ãã³ãèªç¶å ç«ç³»ãæå¶ããããšãçºèŠããç§åŠçç ç©¶
SARS-CoV-2 mRNAã¯ã¯ãã³ã«ããèªç¶å ç«æå¶ãšé¡ããããã®ç ç©¶ã¯ã1æ21æ¥ã«çºè¡šãããŸããïŒ The role of G-quadruplexes, exosomes and microRNAs'ã22幎1æ21æ¥ã«çºè¡šãããmRNA Covid-19ã¯ã¯ãã³ã«ãã£ãŠããããããéºäŒåæ¹å€ã人éã®å¥åº·ã«å€æ§ãªåœ±é¿ãåãŒããšãã蚌æ ã®æ°ã ãæç€ºããŠããŸãã

ç¥çµå€æ§çŸæ£ãšã®çŽæ¥çãªå æé¢ä¿ãããå¯èœæ§ãããïŒ
å¿çç
å ç«æ§è¡å°æ¿æžå°ç
ãã«éº»çº
èçŸæ£
é©å¿å ç«ã®äœäž
è «çãŸãã¯è «çã®ç£çãŸãã¯åœ¢æã®å¢å ïŒ
ããã³DNAæå·
æ¬èª¿æ»ã®è©³çްãªå èš³ã¯ããã¡ããã芧ãã ããã
åèè³æN
Covid-19ã¯ã¯ãã³ãšé¢é£ããçã®çºççãéåžžã«é«ããšããç§åŠçãªç ç©¶çµæãçºè¡šãããŸããã
åèè³æLã®ç ç©¶ããåŒçšãã以äžã®è¡šã¯ã1990幎ãã2021幎12æ12æ¥ãŸã§ã®VAERSããŒã¿ããŒã¹ã«ãããŠãããã瀺ãããã€ãã®çšèªãã³ããã19ã¯ã¯ãã³ã«é¢é£ããŠããŸãã¯ä»ã®ãã¹ãŠã®å©çšå¯èœãªã¯ã¯ãã³ã«é¢é£ããŠçºçããã€ãã³ãã®æ°ãšã2ã€ã®æ°ã®éã®æ¯ã瀺ãã

COVID-19ã¯ã¯ãã³æ¥çš®åŸã®ä¹³ããã®å ±åã¯3åãB现èãªã³ãè «ã®å ±åã¯6å以äžã§ãããæ¿Ÿèæ§ãªã³ãè «ã¯1äŸãé€ãããã¹ãŠCOVID-19ã¯ã¯ãã³ãšé¢é£ããŠããã
èµèããã¯3å以äžã§ãããäžè¡šãç·åãããšãVAERSãžã®ããå ±åã¯ãä»ã®ãã¹ãŠã®ã¯ã¯ãã³ã«é¢é£ãããã®ã«æ¯ã¹ãŠãCOVID-19ã¯ã¯ãã³æ¥çš®ã«é¢é£ãããã®ã2åãå€ãããšãããããŸãããã®ããšã¯ãèè ãã®èŠè§£ã§ã¯ãç·æ¥ã«èª¿æ»ããå¿ èŠã®ããã·ã°ãã«ã§ããã
ããã¯ãéå»1幎éã«mRNAã¯ã¯ãã³ã®æ¥çš®ãåããäººã®æ°ããä»ã®ãã¹ãŠã®ã¯ã¯ãã³æ¥çš®ãšæ¯èŒããŠäžé£ãåãã«å€ããšããèšåã§ã¯èª¬æã§ããŸããã
CDCã®ããŒã¿ã«ãããšã2008幎ãã2020幎ã®éã«ãç±³åœã§ã¯17å2000äžå以äžã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ãããããšãåãã£ãŠããŸããäžæ¹ãã³ããã19ã®æ¥çš®ãã£ã³ããŒã³éå§ãã22幎1æ28æ¥ãŸã§ã«ç±³åœã§æ¥çš®ãããã³ããã19ã®éã¯ãåèš5å4990äžåã§ããã

ã¯ã¯ãã³æ¥çš®ã«é¢é£ããçã®çºççãå¢å ããŠããçç±ã¯ãã³ãã19ã¯ã¯ãã³ãèªç¶å ç«ç³»ãç Žå£ããŠããããã§ããå¯èœæ§ãé«ããããããããšã§ãå ç«ç³»ã¯çãåŒãèµ·ããå¯èœæ§ã®ããä»ã®ææçãšæŠãããšãã§ããªããªããŸãã
äŸãã°ãHPVïŒããããããŒããŠã€ã«ã¹ïŒææã¯ãç¹å®ã®é é žéšãããèéãããåå®®é žããããŸãä»ã®å€ãã®çš®é¡ã®ããã«é¢é£ããŠããŸãããªã³ãè «ããŠã€ã«ã¹ææãšã®é¢é£ãææãããŠããŸãã
ãšã€ãºã«é¢é£ããããã®äžèЧã¯ãã¡ãã§ã芧ããã ããŸãã
æçµåŒè«
ã€ã³ã°ã©ã³ããã¹ã³ããã©ã³ããã«ããã®æ¿åºå ¬åŒããŒã¿ã¯ãã³ããã19泚å°ãçŸå®çã«ãã€ãã¹ã®å¹æãæã€ããšã蚌æããŠããŸãã
ããããã¯ã¯ãã³ã®æå¹æ§ã¯ãå®éã«ã¯ã¯ã¯ãã³ã®ææšã§ã¯ãªããã¯ã¯ãã³æ¥çš®è ã®å ç«ã·ã¹ãã ã®æ§èœããã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®æ§èœãšæ¯èŒããææšã§ãã
ã€ãŸããå®å šãªã¯ã¯ãã³æ¥çš®ãåãã人ã®å ç«ã·ã¹ãã ã¯ãã¯ã¯ãã³æ¥çš®ãåããŠããªã人ã®èªç¶å ç«ã·ã¹ãã ãããå®ã¯å£ã£ãŠããã®ã§ãã
ããããç§ãã¡ãæç¢ºã«ç€ºããããã«ããã®å ç«ã·ã¹ãã ã®å£åã¯é±ããšã«æªåããŠãããã®ã§ãçŸåšãã€ã³ã°ã©ã³ããšã¹ã³ããã©ã³ãã®é«éœ¢è ã匱è ã®éã§ãæ»ã«å¯Ÿããå ç«ã·ã¹ãã ã®æ§èœããã€ãã¹ã«ãªãå§ããŠããŸãã
ãŸããããç§åŠçç ç©¶ã«ãããšãã³ããã19ã¯ã¯ãã³ã¯èªç¶å ç«ç³»ãæå¶ããã¯ã¯ãã³ã«ãã£ãŠããããããéºäŒåçµã¿æãããå ç«æ§è¡å°æ¿æžå°çãå¿ççãªã©ã人éã®å¥åº·ã«ããŸããŸãªåœ±é¿ãåãŒãããšã倿ããŸãããã©ã¡ããèªå·±å ç«çŸæ£ã§ããã
ãŸããåãç ç©¶ã§ãè «çã®çºçã圢æãå¢å ããããšãããããŸãããããã¯ãããã®åå ãšãªãç¹å®ã®ãŠã€ã«ã¹ã«å¯Ÿæã§ããªãå ç«ã·ã¹ãã ã®æå¶ã«åã³é¢é£ããŠããŸãã
AIDSïŒåŸå€©æ§å ç«äžå šçå矀ïŒãšã¯ãå ç«ç³»ãèããæå·ããå Žåã«èµ·ãããçåœãè ããå¯èœæ§ã®ããå€ãã®ææçãç æ°ã衚ãåç§°ã§ãã
åŸå€©æ§å ç«äžå šçå矀ã®äººã¯ãéåžžãå ç«åã®åŒ±ã人ã«ããèµ·ãããªãç¹å®ã®ãããææçã«ããããªã¹ã¯ãé«ããªããŸãã
ãããã£ãŠãã³ããã19泚å°ã¯ãåŸå€©æ§å ç«äžå šçå矀ããã³ããã19ã¯ã¯ãã³èªçºåŸå€©æ§å ç«äžå šçå矀ïŒVAIDSïŒãšããèšãããã®ãªããåæ§ã®å±æ§ãæã€æ°ããªæ°çŸæ£ãåŒãèµ·ãããŠãããšãç§ãã¡ã¯ææ¡ããŸãã
ã¢ã¡ãªã«ãã«ããããªãŒã¹ãã©ãªã¢ããã¥ãŒãžãŒã©ã³ããã€ã®ãªã¹ããšãŒãããã®ã»ãšãã©ã®åœã®æ¿åºããã³ããã19ã®å€§éå°å ¥ä»¥æ¥ã200äžäººã®éå°æ»äº¡ãèšé²ãããããšã確èªããèŠéã鳎ãããŠããã®ããã®ããã§ãã
